Colorectal Cancer Drugs Market Report 2026

The colorectal cancer drugs market size has grown steadily in recent years. It will grow from $21.72 billion in 2025 to $22.78 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increasing incidence of colorectal cancer, advancements in chemotherapy drugs, rising awareness of cancer screening, growth in hospital infrastructure, availability of generic colorectal cancer drugs.

The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $28.57 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to emergence of immunotherapy and targeted therapies, integration of ai in drug development, growth in precision medicine adoption, expansion of oncology research funding, rise in combination treatment protocols. Major trends in the forecast period include personalized cancer therapies, immunotherapy advancements, targeted molecular treatments, early detection & screening technologies, combination therapy approaches.

The rising demand for personalized medicines is expected to drive growth in the colorectal cancer drugs market. Personalized medicine, also called precision medicine, tailors medical treatment and healthcare to individual variations in patients’ genes, environments, and lifestyles. This approach is transforming colorectal cancer (CRC) treatment by providing more individualized and effective care, and it is expected to continue fueling the CRC drug market as research and drug development focus on specific genetic and molecular profiles. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, a notable increase from six approvals in 2022. Therefore, growing demand for personalized medicine is supporting the expansion of the colorectal cancer drugs market.

Key players in the colorectal cancer drugs market are securing FDA approvals for new therapies, such as LONSURF (trifluridine/tipiracil), to enhance market profitability. LONSURF is an oral prescription medication used to treat certain cancers, including colon, rectal, and stomach cancers that have metastasized. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based company, announced FDA approval for LONSURF in combination with bevacizumab for adult patients with metastatic colorectal cancer (mCRC). Compared with LONSURF alone, the combination significantly improved overall survival (OS) and progression-free survival (PFS), with a hazard ratio of 0.61 (95% CI: 0.49-0.77, 1-sided p < 0.001), a median OS of 10.8 months in the combination arm versus 7.5 months with LONSURF alone.

In October 2023, Bristol-Myers Squibb, a US-based pharmaceutical company, acquired Mirati Therapeutics Inc. for $5.8 billion. The acquisition aimed to add KRAZATI, a key lung cancer therapy, to Bristol-Myers Squibb’s commercial portfolio, enhancing and diversifying its oncology offerings. Through this purchase, Mirati’s therapies will reach more patients more quickly, supporting the company’s mission to advance science toward a life free from cancer. Mirati Therapeutics Inc. is a US-based biotechnology company.

Major companies operating in the colorectal cancer drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Servier Laboratories, Eisai Co. Ltd., Taiho Pharmaceutical Co. Ltd., Taiho Oncology Inc., Daiichi Sankyo Company Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

North America was the largest region in the colorectal cancer drugs market in 2025. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the colorectal cancer drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and biologics, particularly affecting segments like VEGF and EGFR inhibitors. Asia-Pacific regions such as China and India, key suppliers of raw materials, face higher costs, causing delays and supply chain adjustments. Hospitals and retail pharmacies see pricing pressures, while some domestic manufacturers benefit from protective tariffs, encouraging local production and innovation in drug formulations.

The colorectal cancer drugs market research report is one of a series of new reports that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Colorectal cancer (CRC), also known as bowel cancer, is a type of cancer that affects the large intestine and rectum. Depending on their origin, these cancers are also referred to as colon tumors or rectal cancer.

The main types of drugs used for colorectal cancer include vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. VEGF inhibitors work by blocking the activity of VEGF and VEGFR. These drugs fall into different classes, including immunotherapy, chemotherapy, and others, and are distributed through hospital pharmacies, retail pharmacies, and other channels.

The colorectal cancer drugs market consists of sales of avastin, bevacizumab, and camptosar. Values in the colorectal cancer drugs market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.